Michael Busch, NP
Family · Saginaw, MINPI 1235680331
Payments from drug & device makers
Across 162 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$552
- AbbVie$417
- AstraZeneca$354
- Otsuka America Pharmaceutical, Inc.$321
- Astellas Pharma US Inc$255
- GSK$231
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,40598%
- Education$802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $552 |
| AbbVie | 18 | $417 |
| AstraZeneca | 16 | $354 |
| Otsuka America Pharmaceutical, Inc. | 12 | $321 |
| Astellas Pharma US Inc | 6 | $255 |
| GSK | 12 | $231 |
| Pfizer | 9 | $153 |
| Boehringer Ingelheim | 7 | $121 |
| Biohaven Pharmaceuticals, Inc. | 3 | $91 |
| Mylan Specialty L.p. | 4 | $87 |
| Bayer | 5 | $84 |
| Xeris Pharmaceuticals, Inc. | 4 | $78 |
| Lilly USA, LLC | 5 | $75 |
| Exact Sciences | 4 | $67 |
| Neurocrine Biosciences, Inc. | 4 | $66 |
| Johnson & Johnson | 2 | $60 |
| Organon | 4 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $51 |
| Novartis | 2 | $48 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Dexcom, Inc. | 2 | $34 |
| Amgen | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Merck | 2 | $31 |
| Corcept Therapeutics | 1 | $27 |
| Abbott | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Lundbeck LLC | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $12 |
How this compares
$3,485 in reported general payments places this provider in the 90th percentile of 3,657 family providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 144 | $176,000 |
| FarxigaDapagliflozin Propanediol | 116 | $110,788 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 102 | $97,088 |
| EliquisApixaban | 75 | $96,421 |
| OzempicSemaglutide | 59 | $85,662 |
| MounjaroTirzepatide | 54 | $64,324 |
| JardianceEmpagliflozin | 38 | $62,336 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $39,721 |
| RexultiBrexpiprazole | 23 | $37,775 |
| JanuviaSitagliptin Phosphate | 22 | $29,614 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $26,635 |
| SymbicortBudesonide/Formoterol Fumarate | 45 | $19,363 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $15,529 |
| EntrestoSacubitril/Valsartan | 13 | $14,788 |
| Spiriva HandihalerTiotropium Bromide | 20 | $14,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $75 | $240,324198 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $354 | $164,632195 claims |
| PfizerEliquis, Nurtec Odt | $153 | $108,87688 claims |
| GSKTrelegy Ellipta, Shingrix | $231 | $99,460114 claims |
| Novo NordiskOzempic | $552 | $85,66259 claims |
| Boehringer IngelheimJardiance | $121 | $62,33638 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $321 | $37,77523 claims |
| MerckJanuvia | $31 | $29,61422 claims |
| NovartisEntresto | $48 | $14,78813 claims |
| BayerKerendia | $84 | $7,13111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,657 family providers in Michigan.
Other family in Saginaw
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.